Investalks 马来西亚中文投资论坛 - 与你一起通往财务自由之路

 找回密码
 注册

最近看过此主题的会员

12
返回列表 发新帖
楼主: aidj

2019新冠病毒 Covid19 疫苗新闻

[复制链接]
x 179
发表于 2020-5-20 10:52 | 显示全部楼层
Why Moderna Stock Plunged Today
The biotech leader is selling stock, leading some investors to take their profits off the table.
Joe Tenebruso
Joe Tenebruso
(TMFGuardian)
May 19, 2020 at 4:46PM
Author Bio
What happened
Shares of Moderna (NASDAQ:MRNA) fell 10% on Tuesday after the biotechnology company said it would seek to raise more than $1.3 billion in cash via a public share offering.

So what
Moderna's stock sale comes soon after it announced positive results from its phase 1 study for its coronavirus vaccine candidate mRNA-1273. Moderna's shares popped 20% on Monday following the news.

Now, it appears that the biotech company is using its stock's gains to sell shares at a higher price. Moderna priced its stock offering at $76 per share, which is about 14% higher than where it closed on Friday.

But the offering price is lower than the price at which Moderna's shares closed on Monday, and its stock price fell in kind.

点评

https://www.sinchew.com.my/pad/con/content_2274921.html 拖累美股下跌·Moderna新冠疫苗报告隐瞒了什么?  发表于 2020-5-20 12:52

x 2 我要送花

x 3008
 楼主| 发表于 2020-5-20 12:50 | 显示全部楼层
aidj 发表于 2020-5-19 08:38
**** 本内容被作者隐藏 ****

人家就是割韭菜!
新冠疫苗受质疑 美股尾盘突然抛售道指跌近400点


ATM观察
4小时前

周二原本有望连续收涨的美股尾盘突然“180度大转弯”、极速抛售,最终道指收跌390点,标普500指数收跌1.05%,纳斯达克指数收跌1.54%。道指、标普500指数在健康新闻网站STAT News对疫苗的质疑报道之下加速抛售势头。该媒体报道对Moderna公司的新冠病毒疫苗试验结果表达了质疑,称该公司并没有披露关键数据以供业界评估其疫苗有效性。



轮到J&J出来割吗?

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-20 14:27 | 显示全部楼层
好心没好报!?

Event 201


FDA pauses coronavirus testing program backed by Bill Gates - New York Daily News
17 hours ago · A coronavirus testing program lauded by billionaire Bill Gates has been indefinitely suspended by the Food and Drug Administration.

游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0

x 1 我要送花

x 179
发表于 2020-5-20 22:18 | 显示全部楼层
Moderna Declines on Skepticism on Coronavirus Vaccine Data
Zacks       
Zacks Equity Research
Zacks20 May 20209 comments
Shares of Moderna, Inc. MRNA fell more than 10% on Tuesday on skepticism related to data announced on Monday by the company from a phase I study evaluating its mRNA-based COVID-19 vaccine candidate, mRNA-1273. The company’s stock was also down 6% in after-hours trading on May 19.

The study is being conducted by National Institute of Allergy and Infectious Diseases (NIAID). Please note that, Moderna has discovered mRNA-1273 and NIAID is developing the candidate in the phase I study under its own investigational new drug (“IND”) application. Moderna will continue development of the candidate in later phases of clinical studies.

Starting the year with its stock price below $20, the company’s shares touched an all-time of $87 on May 18, following the announcement of the phase I study data.

However, a report published on statnews.com raised a few questions regarding the announced clinical data on mRNA-1273, which presumably led to the decline in the stock.

Moderna’s shares have skyrocketed 266.4% so far this year against the industry’s increase of 8.7%, primarily due to the company’s progress with its coronavirus vaccine candidate.


The company announced earlier this week that patients vaccinated with mRNA-1273 achieved levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

The report on statnews.com concluded, after taking into account several vaccine experts, that it is impossible to ascertain the effectiveness of mRNA-1273 as pictured by the company. First, the report states that Moderna revealed very little information with almost no actual data.

Second, NIAID has not released any updates from the clinical study on mRNA-1273 and also declined to comment on Moderna’s announcement.

The statnews.com report states that data from only eight patients out of total 45 and also only two weeks of data following the second dosage also raise concerns related to the durability of the data. Data on majority of patients as well as longer-term data will likely provide clarity on the vaccine’s efficacy. However, we note that the phase I study primarily evaluates a candidate’s safety in human volunteers rather than efficacy.

Moreover, vaccine experts questioned by statnews.com referred to a study in China for discussing level of antibodies. Data from the study showed that level of antibodies in blood sample from naturally recovered COVID-19 patients varies widely. Some patients in the Chinese study also had undetectable neutralizing antibodies. Hence, comparison of level of antibodies generated in patients vaccinated with mRNA-1273, with convalescent sera (level of antibodies seen in blood sample of patients naturally recovered from COVID-19) does not provide a clear picture of the vaccine’s immunogenicity.

Although questions raised by statnews.com report seem genuine with no specific data being made available by Moderna or NIAID, we note that the company has received funding of nearly $500 million from Biomedical Advanced Research and Development Authority ("BARDA"), a government agency. We believe BARDA is funding Moderna’s coronavirus vaccine development due to its strong potential. The FDA has also approved the company’s investigational new drug application to initiate a phase II study to evaluate mRNA-1273, which is expected to begin soon. A phase II study is also set to start in July.

Story continues

x 1 我要送花

x 179
发表于 2020-5-20 22:18 | 显示全部楼层
Moderna Declines on Skepticism on Coronavirus Vaccine Data
Zacks       
Zacks Equity Research
Zacks20 May 20209 comments
Shares of Moderna, Inc. MRNA fell more than 10% on Tuesday on skepticism related to data announced on Monday by the company from a phase I study evaluating its mRNA-based COVID-19 vaccine candidate, mRNA-1273. The company’s stock was also down 6% in after-hours trading on May 19.

The study is being conducted by National Institute of Allergy and Infectious Diseases (NIAID). Please note that, Moderna has discovered mRNA-1273 and NIAID is developing the candidate in the phase I study under its own investigational new drug (“IND”) application. Moderna will continue development of the candidate in later phases of clinical studies.

Starting the year with its stock price below $20, the company’s shares touched an all-time of $87 on May 18, following the announcement of the phase I study data.

However, a report published on statnews.com raised a few questions regarding the announced clinical data on mRNA-1273, which presumably led to the decline in the stock.

Moderna’s shares have skyrocketed 266.4% so far this year against the industry’s increase of 8.7%, primarily due to the company’s progress with its coronavirus vaccine candidate.


The company announced earlier this week that patients vaccinated with mRNA-1273 achieved levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

The report on statnews.com concluded, after taking into account several vaccine experts, that it is impossible to ascertain the effectiveness of mRNA-1273 as pictured by the company. First, the report states that Moderna revealed very little information with almost no actual data.

Second, NIAID has not released any updates from the clinical study on mRNA-1273 and also declined to comment on Moderna’s announcement.

The statnews.com report states that data from only eight patients out of total 45 and also only two weeks of data following the second dosage also raise concerns related to the durability of the data. Data on majority of patients as well as longer-term data will likely provide clarity on the vaccine’s efficacy. However, we note that the phase I study primarily evaluates a candidate’s safety in human volunteers rather than efficacy.

Moreover, vaccine experts questioned by statnews.com referred to a study in China for discussing level of antibodies. Data from the study showed that level of antibodies in blood sample from naturally recovered COVID-19 patients varies widely. Some patients in the Chinese study also had undetectable neutralizing antibodies. Hence, comparison of level of antibodies generated in patients vaccinated with mRNA-1273, with convalescent sera (level of antibodies seen in blood sample of patients naturally recovered from COVID-19) does not provide a clear picture of the vaccine’s immunogenicity.

Although questions raised by statnews.com report seem genuine with no specific data being made available by Moderna or NIAID, we note that the company has received funding of nearly $500 million from Biomedical Advanced Research and Development Authority ("BARDA"), a government agency. We believe BARDA is funding Moderna’s coronavirus vaccine development due to its strong potential. The FDA has also approved the company’s investigational new drug application to initiate a phase II study to evaluate mRNA-1273, which is expected to begin soon. A phase II study is also set to start in July.

Story continues

点评

请问該怎样删除?  发表于 2020-5-20 22:23

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-23 14:42 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-24 21:01 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-24 21:09 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-25 08:28 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0


不是80%哦 暗示着疫苗有一半机率失败

x 1 我要送花

x 3
发表于 2020-5-25 12:43 | 显示全部楼层
aidj 发表于 2020-5-19 20:50
不是说有IgG抗体后,不会被感染吗?

罗斯福号航母14人复阳,多人曾两次转阴

如果体内抗体数量不敌新冠病毒的来袭,该病患会再二度感染。之前也有类似二度感染的新闻报道。

x 0 我要送花

x 3008
 楼主| 发表于 2020-5-25 17:08 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 10 才可浏览,您当前积分为 0


放心好了 全球一定有几百万人感染

x 1 我要送花

x 3008
 楼主| 发表于 2020-5-31 14:10 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 100 才可浏览,您当前积分为 0

x 1 我要送花

x 10646
发表于 2020-6-3 18:38 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 1 才可浏览,您当前积分为 0

x 1 我要送花

x 10646
发表于 2020-6-5 18:55 | 显示全部楼层
游客,本帖隐藏的内容需要积分高于 1 才可浏览,您当前积分为 0

x 0 我要送花

发表回复

您需要登录后才可以回帖 登录 | 注册 |

本版积分规则

Google 搜索本站 搜索WWW

快速回复 返回顶部 返回列表